Regeneron Pharmaceuticals, Inc. and Sanofi announced that the European Commission (EC) has granted marketing authorization for DUPIXENT®(dupilumab), for use in adults with

This content is restricted to site members. If you are an existing user, please log in. New users may register below.

New User Registration
 
 
 
 
 
 
 
 
*Required field